CA19-9 Beyond the Biomarker: Patient Education Hub

CA19-9 Beyond the Biomarker: Patient Education Hub

CA19-9 — the blood test every pancreatic cancer patient gets — is not just a passive indicator of disease; it actively promotes liver metastasis by helping tumor cells stick to liver blood vessels via E-selectin. This mechanistic insight has immediate implications for how patients and clinicians interpret rising CA19-9 levels.

Build a patient and clinician education resource that explains CA19-9's dual role: as a monitoring biomarker AND as a functional driver of liver metastasis. The site would include: accessible explanations of what CA19-9 is, how it's used clinically, what the new evidence shows about its functional role, what therapeutic strategies are now being explored to target it or its receptor E-selectin, and how to find relevant clinical trials.

A clinical trial tracker would specifically aggregate trials targeting CA19-9 (neutralizing antibodies, anti-selectin approaches) or E-selectin in pancreatic cancer. An FAQ section would address common patient questions: 'My CA19-9 went up — what does that mean?' and 'Are there drugs being tested that target CA19-9 directly?'

Pancreatic cancer patients are often well-informed and actively seeking any therapeutic angle. CA19-9 is measured at every clinic visit, making it the most visible number in their disease management. Helping patients understand that this biomarker is now a potential drug target — and that neutralizing it might reduce liver metastasis — empowers more informed conversations with their oncologists and increases trial participation awareness. Anti-selectin drugs already exist in other contexts, creating a realistic near-term therapeutic story to tell.

Who Is This For?

Pancreatic cancer patients and caregivers, pancreatic cancer patient advocacy organizations, and oncologists who want a patient-friendly resource for explaining CA19-9 biology.

Skills & Tools Needed

• Medical writing for patient-accessible content
• Web development (CMS-based educational site)
• ClinicalTrials.gov API integration
• Knowledge of pancreatic cancer biology and CA19-9 biology
• Patient advocacy community connections for dissemination

Feasibility

high — Primarily a content creation and web publishing challenge; the science is clear, the audience is motivated, and a small team with medical writing skills could build a high-value version quickly.

Inspired by: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation